Forbes - Blog Posts

“Never in business history have we seen a single company with so wide of a scope in its operations, so deep of its analytic capabilities, and so committed to embark on such a bold experiment. It’s set to reinvent the retail industry as we know it.“

The Dawn Of The Age Of Responsive Media

This year's CES announcements were more exciting to me than ever before. Sure, we've already seen dozens of drones, exoskeletons, robots, rollable displays, virtual- and augmented-reality headsets, as well as personalized artificial intelligence for smart phones, smart homes, driver-assisted and autonomous cars (aka autonomobiles) and more over the years. They're [...]

Forget about choose-your-own-adventure. Responsive media will offer immersive experiences that adapt “dynamically to the consumer’s attention, engagement and context”.

My latest @forbes article focuses on diverse, young female leaders in crypto policy 🔥

Day Six - Recommended Books

I used to spend quite a lot of time reading books, so here's my highlights;

Good Omens (Terry Pratchett & Neil Gaiman)

The Truth (Terry Pratchett)

Carpe Juguluum (Terry Pratchett)

The Fifth Elephant (Terry Pratchett)

The Janus Man (Colin Forbes)

Snow White and the Seven Samurai (Tom Holt)

Magic Kingdom For Sale - SOLD! (Terry Brooks)

The Bible According to Spike Milligan

Puckoon (Spike Milligan)

The Northern Lights (Phillip Pullman)

The Founding - A Gaunt's Ghosts Omnibus (Dan Abnett)

Of Mice & Men (John Steinbeck)

Fullmetal Alchemist (Manga) (Hiromu Arakawa)

I've had the pleasure of reading pretty much all of the Discworld books by Terry Pratchett and I would happily recommend them to anyone that likes fantasy comedy. If you haven't read one of his books, do it! (And then read the rest... and tell them Nik sent ya)

Nik

How to build value in the drug business: This is a great video from Forbes, This year's two biggest pharma takeouts were Onyx Pharmaceuticals, purchased by Amgen for $10 BIllion, and Bausch + Lomb, a turnaround story sold to Valeant for $8.7 billion. The CEOs from both companies talk about how to revitalize a pharmaceutical firm. The discussion is moderated by Lazard's Kenneth Jacobs.